Krn330 (Not yet branded)
Other Medications
Description
KRN330 is a monoclonal antibody developed for the treatment of metastatic colorectal cancer. This therapeutic antibody has been evaluated both as monotherapy and in combination with irinotecan chemotherapy in patients with advanced colorectal cancer. The drug represents a targeted approach to colorectal cancer treatment, though specific details about its molecular target have not been publicly disclosed in available clinical documentation.
Mechanism of Action
KRN330 functions as a monoclonal antibody that binds to specific antigens expressed on colorectal cancer cells or within the tumor microenvironment. The precise molecular target and downstream signaling pathways affected by KRN330 binding have not been fully characterized in publicly available sources. As a monoclonal antibody, it likely works through mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or direct inhibition of growth signaling pathways.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.